{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:44:50Z","timestamp":1764510290902},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:p>The myeloproliferative disorders have been the \u201cpoor cousins\u201d in the family of hematological malignancies for some time. Recently this field has advanced considerably with the description of a mutation in the JAK2 kinase detectable in the majority of patients and the publication of two landmark clinical trials\u2014ECLAP and MRC PT1. But although both ECLAP and MRC PT1 inform clinical management and allude to the complexities of thrombosis we still lack fundamental knowledge, and our understanding of thrombosis in these conditions has not paralleled advances in the field of thrombosis and vascular biology. The predominant clinical complications of essential thrombocythemia and polycythemia vera are thrombotic and hemorrhagic; these significantly impact upon prognosis and quality of life. Here the current status of our knowledge is reviewed with specific emphasis upon the role of the platelet in the pathogenesis of thrombosis as well as the impact of recent data from ECLAP and MRC PT1.<\/jats:p>","DOI":"10.1182\/asheducation-2005.1.409","type":"journal-article","created":{"date-parts":[[2005,11,22]],"date-time":"2005-11-22T20:29:34Z","timestamp":1132691374000},"page":"409-415","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Platelets and Thrombosis in Myeloproliferative Diseases"],"prefix":"10.1182","volume":"2005","author":[{"given":"Claire N.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111703462209000_R1","doi-asserted-by":"crossref","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u20131061.","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"2019111703462209000_R2","doi-asserted-by":"crossref","unstructured":"James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20131148.","DOI":"10.1038\/nature03546"},{"key":"2019111703462209000_R3","doi-asserted-by":"crossref","unstructured":"Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u20131790.","DOI":"10.1056\/NEJMoa051113"},{"key":"2019111703462209000_R4","doi-asserted-by":"crossref","unstructured":"Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u2013397.","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"2019111703462209000_R5","doi-asserted-by":"crossref","unstructured":"Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114\u2013124.","DOI":"10.1056\/NEJMoa035572"},{"key":"2019111703462209000_R6","doi-asserted-by":"crossref","unstructured":"Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33\u201345.","DOI":"10.1056\/NEJMoa043800"},{"key":"2019111703462209000_R7","doi-asserted-by":"crossref","unstructured":"Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275\u2013290.","DOI":"10.1111\/j.1365-2141.2004.05277.x"},{"key":"2019111703462209000_R8","doi-asserted-by":"crossref","unstructured":"Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31:587\u2013591.","DOI":"10.1002\/hep.510310307"},{"key":"2019111703462209000_R9","doi-asserted-by":"crossref","unstructured":"van Genderen PJ, Lucas IS, van SR, et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost. 1996;76:333\u2013338.","DOI":"10.1055\/s-0038-1650579"},{"key":"2019111703462209000_R10","doi-asserted-by":"crossref","unstructured":"Spivak JL. The optimal management of polycythaemia vera. Br J Haematol. 2002;116:243\u2013254.","DOI":"10.1046\/j.1365-2141.2002.03287.x"},{"key":"2019111703462209000_R11","doi-asserted-by":"crossref","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132\u20131136.","DOI":"10.1056\/NEJM199504273321704"},{"key":"2019111703462209000_R12","doi-asserted-by":"crossref","unstructured":"Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224\u20132232.","DOI":"10.1200\/JCO.2005.07.062"},{"key":"2019111703462209000_R13","doi-asserted-by":"crossref","unstructured":"Burr D, Doss H, Cooke GE, Goldschmidt-Clermont PJ. A meta-analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart disease. Stat Med. 2003;22:1741\u20131760.","DOI":"10.1002\/sim.1375"},{"key":"2019111703462209000_R14","doi-asserted-by":"crossref","unstructured":"Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation. 2001;104:2666\u20132672.","DOI":"10.1161\/hc4701.099787"},{"key":"2019111703462209000_R15","doi-asserted-by":"crossref","unstructured":"Afshar-Kharghan V, Lopez JA, Gray LA, et al. Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinol. 2004;15:21\u201324.","DOI":"10.1097\/00001721-200401000-00004"},{"key":"2019111703462209000_R16","doi-asserted-by":"crossref","unstructured":"Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res. 2002;108:139\u2013145.","DOI":"10.1016\/S0049-3848(02)00354-7"},{"key":"2019111703462209000_R17","doi-asserted-by":"crossref","unstructured":"Blann AD, Marwah S, Serjeant G, Bareford D, Wright J. Platelet activation and endothelial cell dysfunction in sickle cell disease is unrelated to reduced antioxidant capacity. Blood Coagul Fibrinol. 2003;14:255\u2013259.","DOI":"10.1097\/01.mbc.0000061293.28953.8c"},{"key":"2019111703462209000_R18","doi-asserted-by":"crossref","unstructured":"Schafer AI, Turner NA, Handin RI. Platelet lipoxygenase-dependent oxygen burst. Evidence for differential activation of lipoxygenase in intact and disrupted human platelets. Biochim Biophys Acta. 1982;712:535\u2013541.","DOI":"10.1016\/0005-2760(82)90281-8"},{"key":"2019111703462209000_R19","doi-asserted-by":"crossref","unstructured":"Rodriguez-Linares B, Watson SP. Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation. Biochem J. 1996;316:93\u201398.","DOI":"10.1042\/bj3160093"},{"key":"2019111703462209000_R20","doi-asserted-by":"crossref","unstructured":"Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005;280:27251\u201327261.","DOI":"10.1074\/jbc.M501376200"},{"key":"2019111703462209000_R21","doi-asserted-by":"crossref","unstructured":"Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261\u20134266.","DOI":"10.1182\/blood.V96.13.4261"},{"key":"2019111703462209000_R22","doi-asserted-by":"crossref","unstructured":"Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A. 1994;91:8767\u20138771.","DOI":"10.1073\/pnas.91.19.8767"},{"key":"2019111703462209000_R23","doi-asserted-by":"crossref","unstructured":"Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523\u2013530.","DOI":"10.1016\/j.exphem.2005.01.015"},{"key":"2019111703462209000_R24","doi-asserted-by":"crossref","unstructured":"Jensen MK, de Nully BP, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol. 2001;66:143\u2013151.","DOI":"10.1034\/j.1600-0609.2001.00359.x"},{"key":"2019111703462209000_R25","doi-asserted-by":"crossref","unstructured":"Brun M, Bourdoulous S, Couraud PO, et al. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J. 2003;3:215\u2013226.","DOI":"10.1038\/sj.tpj.6500176"},{"key":"2019111703462209000_R26","doi-asserted-by":"crossref","unstructured":"Nahavandi M, Wyche MQ, Perlin E, Tavakkoli F, Castro O. Nitric oxide metabolites in sickle cell anemia patients after oral administration of hydroxyurea; Hemoglobinopathy Hematol. 2000;5:335\u2013339.","DOI":"10.1080\/10245332.2000.11746528"},{"key":"2019111703462209000_R27","doi-asserted-by":"crossref","unstructured":"Pearson TC. Hemorheologic considerations in the pathogenesis of vascular occlusive events in polycythemia vera. Semin Thromb Hemost. 1997;23:433\u2013439.","DOI":"10.1055\/s-2007-996120"},{"key":"2019111703462209000_R28","doi-asserted-by":"crossref","unstructured":"Cortelazzo S, Viero P, Finazzi G et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556\u2013562.","DOI":"10.1200\/JCO.1990.8.3.556"},{"key":"2019111703462209000_R29","unstructured":"Barbui T, Barosi G, Grossi A et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215\u2013232."},{"key":"2019111703462209000_R30","unstructured":"Ruggeri M, Gisslinger H, Tosetto A, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia Am.J Hematol. 2002;71:1\u20136."},{"key":"2019111703462209000_R31","doi-asserted-by":"crossref","unstructured":"Harrison CN, Donohoe S, Carr P, et al. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost. 2002;87:802\u2013807.","DOI":"10.1055\/s-0037-1613087"},{"key":"2019111703462209000_R32","doi-asserted-by":"crossref","unstructured":"Jensen MK, de Nully BP, Thorsen S, Hasselbalch HC. Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. Am J Hematol. 2002;69:185\u2013191.","DOI":"10.1002\/ajh.10054"},{"key":"2019111703462209000_R33","doi-asserted-by":"crossref","unstructured":"Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol. 2005;130:153\u2013165.","DOI":"10.1111\/j.1365-2141.2005.05543.x"},{"key":"2019111703462209000_R34","doi-asserted-by":"crossref","unstructured":"Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293\u20131304.","DOI":"10.1056\/NEJMoa050613"},{"key":"2019111703462209000_R35","unstructured":"Ruggeri M, Castaman G, Rodeghiero F. Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders? Haematologica. 1993;78:18\u201321."},{"key":"2019111703462209000_R36","doi-asserted-by":"crossref","unstructured":"Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005;352:238\u2013244.","DOI":"10.1056\/NEJMoa042087"},{"key":"2019111703462209000_R37","doi-asserted-by":"crossref","unstructured":"Hanft VN, Fruchtman SR, Pickens CV, et al. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000;95:3589\u20133593.","DOI":"10.1182\/blood.V95.11.3589"},{"key":"2019111703462209000_R38","doi-asserted-by":"crossref","unstructured":"Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000;110:577\u2013583.","DOI":"10.1046\/j.1365-2141.2000.02188.x"},{"key":"2019111703462209000_R39","doi-asserted-by":"crossref","unstructured":"Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res. 2005;29:481\u2013491.","DOI":"10.1016\/j.leukres.2004.10.002"},{"key":"2019111703462209000_R40","doi-asserted-by":"crossref","unstructured":"Heis N, Rintelen C, Gisslinger B, et al. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur J Haematol. 1999;62:27\u201331.","DOI":"10.1111\/j.1600-0609.1999.tb01110.x"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/409\/57789\/409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/409\/57789\/409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:46:39Z","timestamp":1573962399000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2005\/1\/409\/19285\/Platelets-and-Thrombosis-in-Myeloproliferative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2005.1.409","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}